Magnetic Nanoparticles for Targeted Cancer Diagnosis, Therapy, and Personalized Treatment

We conducted a prospective, controlled preclinical study of anti-EGFR–targeted superparamagnetic iron-oxide nanoparticles (Fe₃O₄ core with silica interlayer and PEG shell), including a doxorubicin-loaded therapeutic variant, to test imageable delivery and treatment. Mice bearing A431 tumors received IV nanoparticles; magnetic targeting used a ~0.5 T neodymium array (≈15 T/m gradient), magnetothermal activation used an alternating magnetic field (~300 kHz, 10–15 kA/m, 30 min). MRI at 3 T (plus 0.064 T) with multi-echo GRE provided R₂* maps; phantom calibration converted R₂* to tissue iron; ICP-MS served as reference; analyses were performed in SPSS. Magnetic guidance increased intratumoral iron ~2.1–2.9× at 1 h and 24 h by both MRI and ICP-MS (e.g., 1 h MRI 17.8 vs 6.2 µg Fe/g; ICP-MS 18.4 vs 6.6). Imaging quality improved (tumor CNR 6.1 → 14.8 at 1 h; small-lesion <3 mm detection 85%), and node-level performance versus histology was high (sensitivity 87.5%, specificity 88.5%, AUC 0.92). Therapeutically, outcomes progressed from standard care to untargeted MNP-dox to targeted MNP-dox and were best with targeting + hyperthermia (tumor volume change +210% → −10%, median survival 28 → 54 days), with rising TUNEL and 4-HNE signals and manageable safety labs. These results indicate that the same particles can measure (quantitative MRI), steer/activate (magnetic targeting ± hyperthermia), and treat, enabling image-guided selection and adaptive dosing for personalized nanotheranostics.